Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHOP + famotidine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CHOP is a chemotherapy regimen used primarily for non-Hodgkin lymphoma, consisting of cyclophosphamide (C), doxorubicin (H), vincristine (O), and prednisone or prednisolone (P). Famotidine is an H2-receptor antagonist used to reduce stomach acid production. The combination 'CHOP + famotidine' refers to the use of the standard CHOP chemotherapy regimen with the addition of famotidine, likely as supportive care to prevent or treat gastrointestinal side effects such as heartburn or gastritis during cancer treatment. There is no evidence that this combination has a unique name or specific indication beyond supportive care; it is not a recognized therapeutic entity but rather a pragmatic clinical practice.
- Other names
- CHOP plus famotidineCHOP and famotidine
02
Targets
HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on CHOP + famotidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHOP + famotidine.